biological tumor markers

Summary

Summary: Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.

Top Publications

  1. ncbi New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
    P Therasse
    European Organization for Research and Treatment of Cancer, Brussels, Belgium
    J Natl Cancer Inst 92:205-16. 2000
  2. ncbi A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
    Soonmyung Paik
    Division of Pathology, Operation Center, and the Biostatistics Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh 15212, USA
    N Engl J Med 351:2817-26. 2004
  3. ncbi Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
    D J Slamon
    Department of Medicine, U C L A School of Medicine 90024
    Science 244:707-12. 1989
  4. ncbi American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer
    Lyndsay Harris
    Yale Cancer Center, Yale University, New Haven, CT, USA
    J Clin Oncol 25:5287-312. 2007
  5. ncbi Molecular definition of breast tumor heterogeneity
    Michail Shipitsin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Cell 11:259-73. 2007
  6. ncbi Triple-negative breast cancer: clinical features and patterns of recurrence
    Rebecca Dent
    Department of Medical Oncology, Sunnybrook Health Sciences Center, University of Toronto, Ontario, Canada
    Clin Cancer Res 13:4429-34. 2007
  7. ncbi Prognostic and predictive factors in breast cancer by immunohistochemical analysis
    D C Allred
    Department of Pathology, University of Texas Health Science Center, San Antonio 78284, USA
    Mod Pathol 11:155-68. 1998
  8. ncbi Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
    Rafael G Amado
    Amgen, Inc, One Amgen Center Dr, MS 38 2 B, Thousand Oaks, CA 91320 1799, USA
    J Clin Oncol 26:1626-34. 2008
  9. pmc REporting recommendations for tumour MARKer prognostic studies (REMARK)
    L M McShane
    US National Cancer Institute, Bethesda, MD 20892, USA
    Br J Cancer 93:387-91. 2005
  10. ncbi Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma
    Torsten O Nielsen
    Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver Hospital and British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Clin Cancer Res 10:5367-74. 2004

Research Grants

  1. Early Biomarkers of Lung cancer by Gene Array Analysis
    Susan Boggs; Fiscal Year: 2003
  2. DETERMINATION OF A NEW GROWTH FACTOR IN BREAST MILK
    DAVID TAPPER; Fiscal Year: 1992
  3. Phase II Study of 44Gy from 131I-81C6 for CNS Tumors
    David Reardon; Fiscal Year: 2004
  4. Colonoscopy Utilization in North Carolina
    David Ransohoff; Fiscal Year: 2006
  5. Characterization of the Chromosome 17q23 Amplicon
    Fergus Couch; Fiscal Year: 2006
  6. P21 INDUCTION BY BRCA2
    Fergus Couch; Fiscal Year: 2002
  7. CLINICAL RESEARCH CURRICULUM
    David Ransohoff; Fiscal Year: 2004
  8. Methodology of Phase I and II trials of anticancer CAM
    Andrew Vickers; Fiscal Year: 2004
  9. Treatment of Breast Cancer with IGFBP1
    Douglas Yee; Fiscal Year: 2006
  10. MOLECULAR MECHANISMS OF ARA-C THERAPY IN MAN
    Donald Kufe; Fiscal Year: 2005

Detail Information

Publications312 found, 100 shown here

  1. ncbi New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
    P Therasse
    European Organization for Research and Treatment of Cancer, Brussels, Belgium
    J Natl Cancer Inst 92:205-16. 2000
    ..Methods of assessing tumor lesions are better codified, briefly within the guidelines and in more detail in Appendix I. All other aspects of response evaluation have been discussed, reviewed, and amended whenever appropriate...
  2. ncbi A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
    Soonmyung Paik
    Division of Pathology, Operation Center, and the Biostatistics Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh 15212, USA
    N Engl J Med 351:2817-26. 2004
    ..The likelihood of distant recurrence in patients with breast cancer who have no involved lymph nodes and estrogen-receptor-positive tumors is poorly defined by clinical and histopathological measures...
  3. ncbi Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
    D J Slamon
    Department of Medicine, U C L A School of Medicine 90024
    Science 244:707-12. 1989
    ..The data presented further support the concept that the HER-2/neu gene may be involved in the pathogenesis of some human cancers...
  4. ncbi American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer
    Lyndsay Harris
    Yale Cancer Center, Yale University, New Haven, CT, USA
    J Clin Oncol 25:5287-312. 2007
    ..To update the recommendations for the use of tumor marker tests in the prevention, screening, treatment, and surveillance of breast cancer...
  5. ncbi Molecular definition of breast tumor heterogeneity
    Michail Shipitsin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Cell 11:259-73. 2007
    ..Our data suggest prognostic relevance of CD44+ cells and therapeutic targeting of distinct tumor cell populations...
  6. ncbi Triple-negative breast cancer: clinical features and patterns of recurrence
    Rebecca Dent
    Department of Medical Oncology, Sunnybrook Health Sciences Center, University of Toronto, Ontario, Canada
    Clin Cancer Res 13:4429-34. 2007
    ..To compare the clinical features, natural history, and outcomes for women with "triple-negative" breast cancer with women with other types of breast cancer...
  7. ncbi Prognostic and predictive factors in breast cancer by immunohistochemical analysis
    D C Allred
    Department of Pathology, University of Texas Health Science Center, San Antonio 78284, USA
    Mod Pathol 11:155-68. 1998
    ..In the future, these and other factors will be incorporated into a prognostic index that will better reflect the biologic diversity of breast cancer and that will more accurately predict clinical outcome...
  8. ncbi Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
    Rafael G Amado
    Amgen, Inc, One Amgen Center Dr, MS 38 2 B, Thousand Oaks, CA 91320 1799, USA
    J Clin Oncol 26:1626-34. 2008
    ..Although activating mutations in KRAS, a small G-protein downstream of EGFR, correlate with poor response to anti-EGFR antibodies in mCRC, their role as a selection marker has not been established in randomized trials...
  9. pmc REporting recommendations for tumour MARKer prognostic studies (REMARK)
    L M McShane
    US National Cancer Institute, Bethesda, MD 20892, USA
    Br J Cancer 93:387-91. 2005
    ....
  10. ncbi Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma
    Torsten O Nielsen
    Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver Hospital and British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Clin Cancer Res 10:5367-74. 2004
    ..Currently, there exist clinical assays that identify ER+/luminal and HER2-overexpressing tumors, and we sought to develop a clinical assay for breast basal-like tumors...
  11. ncbi Reporting recommendations for tumor marker prognostic studies (REMARK)
    Lisa M McShane
    Biometric Research Branch, National Cancer Institute, Executive Plaza North, 6130 Executive Blvd, Bethesda, MD 20892 7434, USA
    J Natl Cancer Inst 97:1180-4. 2005
    ....
  12. pmc Network-based classification of breast cancer metastasis
    Han Yu Chuang
    Bioinformatics Program, University of California San Diego, La Jolla, CA 92093, USA
    Mol Syst Biol 3:140. 2007
    ..We find that the subnetwork markers are more reproducible than individual marker genes selected without network information, and that they achieve higher accuracy in the classification of metastatic versus non-metastatic tumors...
  13. ncbi X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization
    Robert L Camp
    Department of Pathology, Yale University, School of Medicine, New Haven, Connecticut 06520, USA
    Clin Cancer Res 10:7252-9. 2004
    ....
  14. ncbi Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
    Soonmyung Paik
    Division of Pathology, Operations Center, and Biostatistical Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212, USA
    J Clin Oncol 24:3726-34. 2006
    ..The relationship between the RS and chemotherapy benefit is not known...
  15. ncbi Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series
    Christine Desmedt
    Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Clin Cancer Res 13:3207-14. 2007
    ..The aims of this study conducted by TRANSBIG were to independently validate these results and to compare the outcome with clinical risk assessment...
  16. ncbi ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer
    Gershon Y Locker
    American Society of Clinical Oncology Tumor Markers Expert Panel, Alexandria, VA 22314, USA
    J Clin Oncol 24:5313-27. 2006
    ..To update the recommendations for the use of tumor marker tests in the prevention, screening, treatment, and surveillance of gastrointestinal cancers...
  17. ncbi EGFR and cancer prognosis
    R I Nicholson
    Tenovus Cancer Research Centre, Welsh School of Pharmacy, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff CF10 3XF, UK
    Eur J Cancer 37:S9-15. 2001
    ..Finally, it is important to stress that failure to detect a prognostic significance for EGFR in any one cancer type does not necessarily preclude patients from benefiting from anti-EGFR therapies...
  18. ncbi Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets
    Claus Lindbjerg Andersen
    Molecular Diagnostic Laboratory, Department of Clinical Biochemistry, Aarhus University Hospital, Skejby, DK 8200 Aarhus N, Denmark
    Cancer Res 64:5245-50. 2004
    ..The presented strategy can be applied to evaluate the suitability of any normalization gene candidate in any kind of experimental design and should allow more reliable normalization of RT-PCR data...
  19. pmc Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer
    Gennadi V Glinsky
    Sidney Kimmel Cancer Center, San Diego, California 92121, USA
    J Clin Invest 115:1503-21. 2005
    ....
  20. ncbi Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells
    Li Bing Song
    State Key Laboratory of Oncology in Southern China, Sun Yat sen University Cancer Center, Guangzhou, China
    Cancer Res 66:6225-32. 2006
    ....
  21. ncbi Biomarkers in cancer staging, prognosis and treatment selection
    Joseph A Ludwig
    Genomics and Bioinformatics Group, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Rev Cancer 5:845-56. 2005
    ..Understanding how and when biomarkers can be integrated into clinical care is crucial if we want to translate the promise into reality...
  22. ncbi Relevance of breast cancer cell lines as models for breast tumours: an update
    Marc Lacroix
    Laboratoire Jean Claude Heuson de Cancérologie Mammaire, Institut Jules Bordet, Universite Libre de Bruxelles, Bruxelles, Belgium
    Breast Cancer Res Treat 83:249-89. 2004
    ..Investigations on additional specific lines are expected to improve our knowledge of BCC and of the dialogue that these maintain with their surrounding normal cells in vivo...
  23. ncbi DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy
    Ken A Olaussen
    Laboratory of Radiobiology and Oncology, Commissariat a l Energie Atomique, Fontenay aux Roses, University of Paris 11, Paris, France
    N Engl J Med 355:983-91. 2006
    ..Adjuvant cisplatin-based chemotherapy improves survival among patients with completely resected non-small-cell lung cancer, but there is no validated clinical or biologic predictor of the benefit of chemotherapy...
  24. ncbi Autoantibody signatures in prostate cancer
    Xiaoju Wang
    Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    N Engl J Med 353:1224-35. 2005
    ..New biomarkers, such as autoantibody signatures, may improve the early detection of prostate cancer...
  25. ncbi The PIK3CA gene is mutated with high frequency in human breast cancers
    Kurtis E Bachman
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Department of Oncology, Baltimore, Maryland 21231, USA
    Cancer Biol Ther 3:772-5. 2004
    ..These results demonstrate that PIK3CA is the most mutated oncogene in breast cancer and support a role for PIK3CA in epithelial carcinogenesis...
  26. ncbi Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells
    Michael F Clarke
    Stanford University School of Medicine, Stanford, California, USA
    Cancer Res 66:9339-44. 2006
  27. ncbi Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients
    Robert L Yauch
    Department of Molecular Diagnostics, Genentech, Inc, South San Francisco, California 94080, USA
    Clin Cancer Res 11:8686-98. 2005
    ..These data support a potential role for EMT as a determinant of EGFR activity in NSCLC tumor cells and E-cadherin expression as a novel biomarker predicting clinical activity of the EGFR inhibitor erlotinib in NSCLC patients...
  28. ncbi Proliferation marker Ki-67 in early breast cancer
    Ander Urruticoechea
    Academic Department of Biochemistry, Royal Marsden Hospital, London SW3 6JJ, United Kingdom
    J Clin Oncol 23:7212-20. 2005
    ..However, its application as a pharmacodynamic intermediate marker of the effectiveness of medical therapy holds great promise for rapid evaluation of new drugs...
  29. ncbi Common markers of proliferation
    Michael L Whitfield
    Department of Genetics and Norris Cotton Cancer Center, Dartmouth Medical School, 7400 Remsen, Hanover, New Hampshire 03755, USA
    Nat Rev Cancer 6:99-106. 2006
    ..Can the proliferation signature be used to improve our understanding of the cell cycle and cancer pathogenesis, as well as being used as a biomarker for cancer diagnosis and prognosis?..
  30. ncbi The cancer biomarker problem
    Charles L Sawyers
    Howard Hughes Medical Institute, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10065, USA
    Nature 452:548-52. 2008
    ..One of the main barriers to further progress is identifying the biological indicators, or biomarkers, of cancer that predict who will benefit from a particular targeted therapy...
  31. ncbi Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer
    Bruce G Haffty
    Department of Radiation Oncology, Cancer Institute of New Jersey, Robert Wood Johnson Medical School University of Medicine and Dentistry of New Jersey, New Brunswick, NJ 08903 2681, USA
    J Clin Oncol 24:5652-7. 2006
    ..To determine the prognostic significance of triple negative breast cancers with respect to locoregional relapse and distant metastasis in conservatively managed breast cancer patients...
  32. pmc Gene expression profiling identifies clinically relevant subtypes of prostate cancer
    Jacques Lapointe
    Department of Pathology, Stanford University, Stanford, CA 94305, USA
    Proc Natl Acad Sci U S A 101:811-6. 2004
    ..Our results suggest that prostate tumors can be usefully classified according to their gene expression patterns, and these tumor subtypes may provide a basis for improved prognostication and treatment stratification...
  33. ncbi Gene expression profiling of primary cutaneous melanoma and clinical outcome
    Veronique Winnepenninckx
    Department of Pathology, Gustave Roussy Institute, 94805 Villejuif Cedex, France
    J Natl Cancer Inst 98:472-82. 2006
    ..To identify differentially expressed genes that may be involved in melanoma progression and prognosis, we investigated the relationship between gene expression profiles and clinical outcome in a cohort of patients with primary melanoma...
  34. ncbi Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri
    R Klaes
    Division of Molecular Diagnostics and Therapy, Department of Surgery, University of Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany
    Int J Cancer 92:276-84. 2001
    ..These data demonstrate that p16(INK4a) is a specific biomarker to identify dysplastic cervical epithelia in sections of cervical biopsy samples or cervical smears...
  35. ncbi Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence
    Tetsuya Mitsudomi
    Department of Thoracic Surgery, Aichi Cancer Center Hospital, 1 1 Kanokoden, Chikusa ku, Nagoya 464 8681, Japan
    J Clin Oncol 23:2513-20. 2005
    ..To evaluate the relationship between mutations of the epidermal growth factor receptor (EGFR) gene and the effectiveness of gefitinib treatment in patients with recurrent lung cancer after pulmonary resection...
  36. ncbi Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer
    Zhen Zhang
    Department of Pathology, Biomarker Discovery Center, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Cancer Res 64:5882-90. 2004
    ..These biomarkers demonstrated the potential to improve the detection of early stage ovarian cancer...
  37. ncbi Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma
    Danit Lebanony
    Rosetta Genomics Ltd, 10 Plaut St, Rehovot 76706, Israel
    J Clin Oncol 27:2030-7. 2009
    ..In this study, we set out to identify specific microRNA biomarkers for the identification of squamous cell carcinoma, and to use such markers for the development of a standardized assay...
  38. ncbi The human plasma proteome: a nonredundant list developed by combination of four separate sources
    N Leigh Anderson
    The Plasma Proteome Institute, Washington DC 20009 3450, USA
    Mol Cell Proteomics 3:311-26. 2004
    ..The resulting nonredundant list confirms the presence of a number of interesting candidate marker proteins in plasma and serum...
  39. ncbi Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma
    Brian I Rini
    Department of Solid Tumor Oncology and Urology, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Avenue, Desk R35, Cleveland, OH 44195, USA
    J Clin Oncol 26:3743-8. 2008
    ..To assess the safety and efficacy of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma (mRCC) and explore biomarkers for sunitinib response...
  40. ncbi MGMT promoter methylation and field defect in sporadic colorectal cancer
    Lanlan Shen
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Natl Cancer Inst 97:1330-8. 2005
    ..The DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) is frequently methylated in colorectal cancer. We hypothesized that MGMT methylation could be one of the mediators of field cancerization in the colon mucosa...
  41. ncbi Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer
    Yixin Wang
    Veridex, LLC, a Johnson and Johnson Company, 3210 Merryfield Row, San Diego, CA 92121, USA
    J Clin Oncol 22:1564-71. 2004
    ..In this study, we used DNA chip technology to systematically identify new prognostic markers for tumor relapse in Dukes' B patients...
  42. pmc Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future
    R D Riley
    Department of Epidemiology and Public Health, University of Leicester, Leicester, UK
    Br J Cancer 88:1191-8. 2003
    ..Such changes in practice would help important evidence-based reviews to be conducted in order to establish the most appropriate prognostic markers for clinical use, which should ultimately improve patient care...
  43. ncbi Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer
    Takao Kamai
    Department of Urology, Dokkyo University School of Medicine, Tochigi 321 0293, Japan
    Clin Cancer Res 9:2632-41. 2003
    ..We investigated the roles of Rho and ROCK in bladder cancer...
  44. ncbi Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas
    Ronny Drapkin
    Department of Cancer Biology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Res 65:2162-9. 2005
    ..Its expression in cortical inclusion cysts suggests that formation of Mullerian epithelium is a prerequisite step in the development of some types of EOCs...
  45. ncbi Urokinase plasminogen activator: a prognostic marker in multiple types of cancer
    M J Duffy
    Department of Nuclear Medicine, St Vincent s Hospital, University College of Dublin, Ireland
    J Surg Oncol 71:130-5. 1999
    ..uPA is also prognostic in other malignancies, such as gastric, colorectal, esophageal, renal, endometrial, and ovarian cancers. uPA may thus be a prognostic indicator for multiple types of adenocarcinoma...
  46. ncbi Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival
    J Rubin Grandis
    Department of Otolaryngology, University of Pittsburgh School of Medicine, and University of Pittsburgh Cancer Institute, PA, USA
    J Natl Cancer Inst 90:824-32. 1998
    ....
  47. ncbi Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation
    William C S Cho
    Department of Clinical Oncology, Room 1305, 3 F, Block R, Queen Elizabeth Hospital, 30 Gascoigne Road, Kowloon, Hong Kong
    Eur J Cancer 45:2197-206. 2009
    ..The present study focuses on the microRNA (miRNA) expression profiles of this important subset of lung cancer...
  48. ncbi Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype
    Maggie C U Cheang
    Genetic Pathology Evaluation Centre, Vancouver Coastal Health Research Institute, British Columbia Cancer Agency, and University of British Columbia, Vancouver, British Columbia, Canada
    Clin Cancer Res 14:1368-76. 2008
    ..This study directly compares the prognostic significance between three- and five-biomarker surrogate panels to define intrinsic breast cancer subtypes, using a large clinically annotated series of breast tumors...
  49. ncbi The polycomb group protein EZH2 is involved in progression of prostate cancer
    Sooryanarayana Varambally
    Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
    Nature 419:624-9. 2002
    ..Thus, dysregulated expression of EZH2 may be involved in the progression of prostate cancer, as well as being a marker that distinguishes indolent prostate cancer from those at risk of lethal progression...
  50. ncbi Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review
    M Berwick
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Natl Cancer Inst 92:874-97. 2000
    ..The evolving ability to study polymorphisms in DNA repair genes may contribute to new understandings about the mechanisms of DNA repair and the way in which DNA repair capacity affects the development of cancer...
  51. ncbi Unique microRNA molecular profiles in lung cancer diagnosis and prognosis
    Nozomu Yanaihara
    Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Cancer Cell 9:189-98. 2006
    ..These results indicate that miRNA expression profiles are diagnostic and prognostic markers of lung cancer...
  52. ncbi Prognostic value of ERBB family mRNA expression in breast carcinomas
    Ivan Bieche
    Laboratoire d Oncogénétique INSERM E0017, Centre Rene Huguenin, St Cloud, France
    Int J Cancer 106:758-65. 2003
    ....
  53. pmc Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum
    John B Welsh
    Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, CA 92121, USA
    Proc Natl Acad Sci U S A 100:3410-5. 2003
    ....
  54. pmc Metalloproteinases: role in breast carcinogenesis, invasion and metastasis
    M J Duffy
    Department of Nuclear Medicine, St Vincent s Hospital, Dublin, Ireland
    Breast Cancer Res 2:252-7. 2000
    ..Because MMPs are apparently involved in breast cancer initiation and dissemination, inhibition of these proteinases may be of value both in preventing breast cancer and in blocking metastasis of established tumours..
  55. pmc HER-2 gene amplification can be acquired as breast cancer progresses
    Songdong Meng
    Cancer Immunobiology Center, University of Texas Southwestern Medical Center, 6000 Harry Hines Boulevard, Dallas, TX 75390, USA
    Proc Natl Acad Sci U S A 101:9393-8. 2004
    ..e., 37.5% (95% confidence interval of 18.8-59.4%). Four of the 9 patients were treated with Herceptin-containing therapy. One had a complete response and 2 had a partial response...
  56. ncbi Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up
    Markku Miettinen
    Departments of Soft Tissue Pathology, Armed Forces Institute of Pathology, Washington, DC 20306 6000, USA
    Am J Surg Pathol 29:52-68. 2005
    ..The above results may be helpful for setting the criteria for adjuvant treatment such as Gleevec...
  57. ncbi Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer
    Mitch Dowsett
    Academic Department of Biochemistry, 4th Floor, Wallace Wing, The Royal Marsden Hospital, Fulham Road, London SW3 6 JJ, UK
    J Natl Cancer Inst 99:167-70. 2007
    ....
  58. ncbi Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer
    Federica Di Nicolantonio
    Laboratory of Molecular Genetics, The Oncogenomics Center, Institute for Cancer Research and Treatment, University of Torino, Medical School, Candiolo, Torino, Italy
    J Clin Oncol 26:5705-12. 2008
    ..Double-hit therapies aimed at simultaneous inhibition of epidermal growth factor receptor and BRAF warrant exploration in CRC patients carrying the V600E oncogenic mutation...
  59. ncbi Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines
    Samir E Witta
    Department of Medicine Medical Oncology, University of Colorado Health Sciences Center and University of Colorado Cancer Center, Campus Box 8117, PO Box 6511, Aurora, CO 80045, USA
    Cancer Res 66:944-50. 2006
    ..Thus, combined HDAC inhibitor and gefitinib treatment represents a novel pharmacologic strategy for overcoming resistance to EGFR inhibitors in patients with lung cancer...
  60. ncbi Molecular identification of an IgE-dependent histamine-releasing factor
    S M MacDonald
    Department of Medicine, Johns Hopkins University School of Medicine, Johns Hopkins Asthma and Allergy Center, Baltimore, MD 21224, USA
    Science 269:688-90. 1995
    ..Polyclonal antibodies recognized and removed the biological activity of recombinant and native HRF. HRF identifies a heterogeneity of IgE and is believed to play a prominent role in chronic allergic disease processes...
  61. pmc Regularized gene selection in cancer microarray meta-analysis
    Shuangge Ma
    Department of Epidemiology and Public Health, Yale University, New Haven, CT 06520, USA
    BMC Bioinformatics 10:1. 2009
    ..The meta analysis of cancer microarray data is challenging because of the high dimensionality of gene expressions and the differences in experimental settings amongst different experiments...
  62. ncbi Cancer epigenomics: DNA methylomes and histone-modification maps
    Manel Esteller
    Cancer Epigenetics Laboratory, Spanish National Cancer Centre CNIO, Melchor Fernandez Almagro 3, 28029 Madrid, Spain
    Nat Rev Genet 8:286-98. 2007
    ..It is time to 'upgrade' cancer epigenetics research and put together an ambitious plan to tackle the many unanswered questions in this field using epigenomics approaches...
  63. ncbi The role of C-reactive protein as a prognostic indicator in advanced cancer
    Fade Aziz Mahmoud
    Taussig Cancer Center, The Cleveland Clinic Foundation, M76, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Curr Oncol Rep 4:250-5. 2002
    ..Measurement of CRP is simple, cheap, and routine and provides valuable information in palliative care...
  64. ncbi Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort
    Steven A Belinsky
    Lung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, New Mexico 87108, USA
    Cancer Res 66:3338-44. 2006
    ....
  65. ncbi Micro-RNA profiling in kidney and bladder cancers
    Fedra Gottardo
    Department of Urology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Urol Oncol 25:387-92. 2007
    ..To study the role of the micro-RNAs in human kidney and bladder cancer, we analyzed the expression profile of 245 micro-RNAs in kidney and bladder primary tumors...
  66. ncbi Diagnostic markers for early detection of ovarian cancer
    Irene Visintin
    Department of Obstetrics and Gynecology, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Clin Cancer Res 14:1065-72. 2008
    ..In this study, we characterize and validate the combination of six serum biomarkers that discriminate between disease-free and ovarian cancer patients with high efficiency...
  67. pmc Transcriptional patterns, biomarkers and pathways characterizing nasopharyngeal carcinoma of Southern China
    Weiyi Fang
    Cancer Research Institute of Southern Medical University, Key Lab for Transcriptomics and Proteomics of Human Fatal Diseases Supported by Ministry of Education and Guangdong Province, 510515, PR China
    J Transl Med 6:32. 2008
    ....
  68. pmc Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas
    Bas Kreike
    Division of Radiation Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Breast Cancer Res 9:R65. 2007
    ..We examined the histopathological and gene-expression profile of triple-negative tumors to define subgroups with specific characteristics, including risk of developing distant metastases...
  69. ncbi Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer
    D M Aebersold
    Department of Radiation Oncology, University of Bern, Switzerland
    Cancer Res 61:2911-6. 2001
    ....
  70. ncbi Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer
    Giuseppe Viale
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Via Ripamoniti 435, Milan, Italy
    J Natl Cancer Inst 100:207-12. 2008
    ..Thus, Ki-67 labeling index was an independent prognostic factor but was not predictive of better response to adjuvant chemotherapy in these studies...
  71. pmc Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer
    L M Forrest
    University Department of Surgery, Royal Infirmary, Glasgow G31 2ER, UK
    Br J Cancer 89:1028-30. 2003
    ..001) was comparable in prognostic value to that based on stage and performance status (HR 1.48, 95% CI 1.12 - 1.95, P=0.006) in patients with inoperable non-small-cell lung cancer. The former is simple to measure and well standardised...
  72. pmc Loss of Ep-CAM (CO17-1A) expression predicts survival in patients with gastric cancer
    I Songun
    Department of Surgery, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands
    Br J Cancer 92:1767-72. 2005
    ..Loss of Ep-CAM-expression identifies aggressive tumours especially in patients with stage I and II disease. This information may be helpful in selecting patients suitable for surgery or for additional treatment pre- or postoperatively...
  73. ncbi Prognostic factors in non-small cell lung cancer: a decade of progress
    Michael D Brundage
    Department of Oncology, Radiation Oncology Research Unit, Queen s University, Kingston, ON, Canada
    Chest 122:1037-57. 2002
    ....
  74. ncbi The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass
    Richard G Moore
    Women and Infants Hospital, Brown University, Providence, RI 02925, USA
    Gynecol Oncol 108:402-8. 2008
    ..Because elevated CA125 levels occur in many benign gynecologic conditions, we set out to identify other novel biomarkers that would increase the sensitivity and specificity of CA125...
  75. ncbi Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis
    R Bos
    Department of Pathology, Free University Hospital, Amsterdam, The Netherlands
    J Natl Cancer Inst 93:309-14. 2001
    ..Increased levels of HIF-1 alpha are associated with increased proliferation and increased expression of ER and VEGF. Thus, increased levels of HIF-1 alpha are potentially associated with more aggressive tumors...
  76. ncbi Identification of prognostic factors in patients with brain metastases: a review of 1292 patients
    F J Lagerwaard
    Department of Radiation Oncology, Daniel den Hoed Cancer Center, University Hospital Rotterdam, The Netherlands
    Int J Radiat Oncol Biol Phys 43:795-803. 1999
    ..Prognostic factors in 1292 patients with brain metastases, treated in a single institution were identified in order to determine subgroups of patients suitable for selection in future trials...
  77. ncbi Genes expressed in human tumor endothelium
    B St Croix
    Johns Hopkins Oncology Center, Howard Hughes Medical Institute, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Science 289:1197-202. 2000
    ..These studies demonstrate that tumor and normal endothelium are distinct at the molecular level, a finding that may have significant implications for the development of anti-angiogenic therapies...
  78. ncbi Hypermethylation of CpG islands in primary and metastatic human prostate cancer
    Srinivasan Yegnasubramanian
    Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, 1650 Orleans Street, Baltimore, MD 21231 1000, USA
    Cancer Res 64:1975-86. 2004
    ..Furthermore, CpG island hypermethylation patterns in prostate cancer metastases were very similar to the primary prostate cancers and tended to show greater differences between cases than between anatomical sites of metastasis...
  79. ncbi 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology
    R C Bast
    American Society of Clinical Oncology, Alexandria, VA 22314, USA
    J Clin Oncol 19:1865-78. 2001
    ..These guidelines are intended for use in the care of patients outside of clinical trials...
  80. ncbi Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer
    K S Goonetilleke
    Department of Surgery, Hepatobiliary Surgical Unit, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, UK
    Eur J Surg Oncol 33:266-70. 2007
    ..This systematic review examines studies using biochemical markers for the diagnosis of pancreatic cancer in order to appraise their role in contemporary management algorithms...
  81. pmc A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer
    Shuji Ogino
    Center for Molecular Oncologic Pathology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Natl Cancer Inst 100:1734-8. 2008
    ..In conclusion, tumoral LINE-1 hypomethylation is independently associated with shorter survival among colon cancer patients...
  82. ncbi Immunohistochemical characteristics of melanoma
    Steven J Ohsie
    Department of Pathology and Laboratory Medicine, Geffen UCLA School of Medicine, Los Angeles, CA 90095 1732, USA
    J Cutan Pathol 35:433-44. 2008
    ..Ki67 remains the most useful adjunct in distinguishing benign from malignant melanocytic tumors. None of the markers reviewed has been shown conclusively to have prognostic value for melanocytic neoplasms...
  83. pmc Symbiotic bacteria direct expression of an intestinal bactericidal lectin
    Heather L Cash
    Center for Immunology, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA
    Science 313:1126-30. 2006
    ..We propose that these proteins represent an evolutionarily primitive form of lectin-mediated innate immunity, and that they reveal intestinal strategies for maintaining symbiotic host-microbial relationships...
  84. pmc Use of immunohistochemical markers can refine prognosis in triple negative breast cancer
    Marc Tischkowitz
    Program in Cancer Genetics, McGill University, Montreal, Quebec, Canada
    BMC Cancer 7:134. 2007
    ..The IHC pattern that best defines basal-like tumors is under investigation and various combinations of ER, PR, HER2-, CK5/6+ and EGFR+ have been tested...
  85. ncbi Enabling personalized cancer medicine through analysis of gene-expression patterns
    Laura J Van't Veer
    Agendia BV, Louwesweg 6, 1066 EC Amsterdam, The Netherlands
    Nature 452:564-70. 2008
    ..In particular, tests that predict the clinical outcome for patients on the basis of the genes expressed by their tumours are likely to increasingly affect patient management, heralding a new era of personalized medicine...
  86. ncbi Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours
    P B Vermeulen
    Department of Pathology, University Hospital Antwerp, Edegem, Antwerp, Belgium
    Eur J Cancer 38:1564-79. 2002
  87. ncbi DNA methylation biomarkers for blood-based colorectal cancer screening
    Catherine Lofton-Day
    Epigenomics, Inc, Seattle, WA, USA
    Clin Chem 54:414-23. 2008
    ..We describe a sieving strategy for identifying high-performing marker assays that detect colorectal cancer (CRC)-specific methylated DNA in plasma...
  88. ncbi Penalized Cox regression analysis in the high-dimensional and low-sample size settings, with applications to microarray gene expression data
    Jiang Gui
    Department of Statistics, University of California Davis, CA 95616, USA
    Bioinformatics 21:3001-8. 2005
    ..It would be desirable to have models with good prediction accuracy and parsimony property...
  89. ncbi Gene expression profiling of breast cell lines identifies potential new basal markers
    E Charafe-Jauffret
    Marseille Cancer Institute, Laboratory of Molecular Oncology, Inserm Institut Paoli Calmettes, Marseille, France
    Oncogene 25:2273-84. 2006
    ....
  90. pmc A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass
    Richard G Moore
    Program in Women s Oncology, Women and Infants Hospital, Brown University, Providence, RI 02925, USA
    Gynecol Oncol 112:40-6. 2009
    ..The objective of this trial was to validate a predictive model to assess the risk for EOC in women with a pelvic mass...
  91. ncbi High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer
    Gilbert Spizzo
    Division of Haematology and Oncology, University of Innsbruck, Innsbruck, Austria
    Breast Cancer Res Treat 86:207-13. 2004
    ....
  92. ncbi Breast cancer metastasis: markers and models
    Britta Weigelt
    Division of Experimental Therapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Nat Rev Cancer 5:591-602. 2005
    ..These data have important implications for prognosis prediction and our understanding of metastasis...
  93. ncbi Self-renewal and solid tumor stem cells
    Muhammad Al-Hajj
    University of Michigan Medical School, CCGC Room 4410, 1500 E Medical Center Drive, Ann Arbor 48109 0936, USA
    Oncogene 23:7274-82. 2004
    ..This suggests that agents that target the defective self-renewal pathways in cancer cells might lead to improved outcomes in the treatment of these diseases...
  94. pmc Plk phosphorylation regulates the microtubule-stabilizing protein TCTP
    Frederic R Yarm
    Department of Molecular and Cellular Biology, Harvard University, Cambridge, Massachusetts 02138, USA
    Mol Cell Biol 22:6209-21. 2002
    ..These results suggest that phosphorylation decreases the microtubule-stabilizing activity of TCTP and promotes the increase in microtubule dynamics that occurs after metaphase...
  95. ncbi The Ki-67 protein: from the known and the unknown
    T Scholzen
    Division of Molecular Immunology, Research Center Borstel, Germany
    J Cell Physiol 182:311-22. 2000
    ..There are indications, however, that Ki-67 protein expression is an absolute requirement for progression through the cell-division cycle...
  96. pmc An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer
    Andrew E Teschendorff
    Breast Cancer Functional Genomics Laboratory, Cancer Research UK Cambridge Research Institute and Department of Oncology, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK
    Genome Biol 8:R157. 2007
    ..Reliable identification of ER-negative tumors that have a good prognosis is not yet possible...
  97. ncbi Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast
    L G Fulford
    The Breakthrough Breast Cancer Research Centre, London, UK
    Histopathology 49:22-34. 2006
    ..Currently, they are not identified in routine practice and no morphological guidelines exist to aid their identification. The aim of this study was to analyse the histological features of CK14+ IDC...
  98. pmc Early detection of ovarian cancer
    Donna Badgwell
    Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Dis Markers 23:397-410. 2007
    ..The development of technologies that measure multiple serum markers simultaneously, linked to the creation of statistical methods that enhance sensitivity without sacrificing specificity hold great promise...
  99. ncbi Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules
    Giuseppe Costante
    Dipartimento di Medicina Sperimentale e Clinica, Università Magna Graecia, Italy
    J Clin Endocrinol Metab 92:450-5. 2007
    ..Routine serum calcitonin (CT) measurement in patients with thyroid nodules for diagnosis of medullary thyroid carcinoma (MTC) is controversial...
  100. pmc High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer
    Tibor A Rauch
    Divisions of Biology, Information Sciences, and Surgery, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA
    Proc Natl Acad Sci U S A 105:252-7. 2008
    ..The results are consistent with a specific defect in methylation of repetitive DNA sequences in human cancer...
  101. ncbi Gene silencing in cancer in association with promoter hypermethylation
    James G Herman
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins Medical Institutions, Baltimore, USA
    N Engl J Med 349:2042-54. 2003

Research Grants77

  1. Early Biomarkers of Lung cancer by Gene Array Analysis
    Susan Boggs; Fiscal Year: 2003
    ..Expression profiling is expected to provide a new approach for comparisons between normal and cancerous cells, as well as to suggest potential targets for intervention. ..
  2. DETERMINATION OF A NEW GROWTH FACTOR IN BREAST MILK
    DAVID TAPPER; Fiscal Year: 1992
    ..a critical role in modulating both normal and abnormal cellular proliferation and may have potential as biological tumor markers. During our prior granting period, we identified specific growth factor activities in milk of substrains ..
  3. Phase II Study of 44Gy from 131I-81C6 for CNS Tumors
    David Reardon; Fiscal Year: 2004
    ..To further define the toxicity of this approach and Specific Aim 3.To determine the impact of this therapy on quality of life. ..
  4. Colonoscopy Utilization in North Carolina
    David Ransohoff; Fiscal Year: 2006
    ..It may provide the basis to develop interventions to optimize the allocation of colonoscopy effort in programs of CRC screening and surveillance. ..
  5. Characterization of the Chromosome 17q23 Amplicon
    Fergus Couch; Fiscal Year: 2006
    ..Thus, the project may involve a complete transition from benchtop to bedside. Finally, the amplified and overexpressed genes may prove useful as important targets of gene, pharmacological, and immunological therapy in the future. ..
  6. P21 INDUCTION BY BRCA2
    Fergus Couch; Fiscal Year: 2002
    ....
  7. CLINICAL RESEARCH CURRICULUM
    David Ransohoff; Fiscal Year: 2004
    ..abstract_text> ..
  8. Methodology of Phase I and II trials of anticancer CAM
    Andrew Vickers; Fiscal Year: 2004
    ....
  9. Treatment of Breast Cancer with IGFBP1
    Douglas Yee; Fiscal Year: 2006
    ..Our long-term goal is to prove that the IGFs are key targets for the treatment of breast cancer. By optimizing IGF neutralization strategies, we will be prepared to move this anti-IGF strategy into the clinic. ..
  10. MOLECULAR MECHANISMS OF ARA-C THERAPY IN MAN
    Donald Kufe; Fiscal Year: 2005
    ..abstract_text> ..
  11. Non-viral Cutaneous Gene Delivery
    Mohammed Kashani Sabet; Fiscal Year: 2005
    ..We will determine whether efficient expression of the XPC gene in mice will alter the response to UV-mediated DNA damage. ..
  12. Luminal Lipid Exposure, Genetics and Colon Cancer Risk
    Ikuko Kato; Fiscal Year: 2006
    ..In addition, accumulated dietary data and biological specimens will serve as an important resource for future research on other nutrient-gene interactions. ..
  13. GREENBAUM CANCER CENTER, UNIVERSITY OF MARYLAND
    Kevin Cullen; Fiscal Year: 2004
    ..The P-20 is a crucial landmark and will provide support to advance programmatic activities and enhance translational research towards the goal of a P-30 Grant Award. ..
  14. Prognostic Markers in Trials for Head and Neck Cancer
    Kevin Cullen; Fiscal Year: 2005
    ..3. To develop tissue microarrays based on the samples in specific aims 1 and 2 for focused screening and validation of additional cellular factors as determinants of clinical response and outcome. ..
  15. Human Gut Microflora Profiling for Population Studies
    Johanna Lampe; Fiscal Year: 2006
    ..abstract_text> ..
  16. GLUTATHIONE TRANSFERASES IN HUMANS: DIETARY INFLUENCES
    Johanna Lampe; Fiscal Year: 2006
    ..abstract_text> ..
  17. Screening for Colorectal Cancer: An Integrated Approach
    Kathryn Phillips; Fiscal Year: 2007
    ..We will focus particularly on the influence of (a) utilization rates (Aim #1) and (b) patient preferences for current and new screening methods (Aim #2). ..
  18. CARCINOGENIC CYCLIC NITROSAMINE DNA ADDUCTS
    Stephen S Hecht; Fiscal Year: 2010
    ..The proposed research is significant because of the known human exposure to these carcinogens through the diet, tobacco products, and endogenous formation. ..
  19. Determinants of Resistance to Erlotinib in NSCLC
    Roman Perez Soler; Fiscal Year: 2010
    ..To confirm the predictive value of the algorithm in a group of patients with chemoresistant NSCLC selected for their high probability of achieving a response or stable disease with single agent erlotinib therapy. ..
  20. CaP Metastasis Biomarkers: Validation/Genomics/Biology
    Pamela Paris; Fiscal Year: 2009
    ..von Eschenbach. ..
  21. THE EFFECT OF LYCOPENE ON IGF-1 ACTIVITY AND SECRETION IN PRIMARY CULTURES OF PRO
    Larisa Nonn; Fiscal Year: 2008
    ..Once we have determined lycopene's effect on the IGF-1-induced actions in normal prostatic cells, this effect will be compared to those on cells derived from adenocarcinoma. [unreadable] [unreadable] [unreadable]..
  22. Pilot Study of Genetic and Psychosocial Determinants of HPA Responsivity
    Joanne Dorgan; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  23. O-GlcNAc:Developing New Tool for Assessment of Glycemia
    Gerald Hart; Fiscal Year: 2008
    ..The project also represents a new inter-disciplinary, inter-departmental basic science-clinical research collaboration between Biological Chemistry and The Department of Medicine. ..
  24. Inflammatory Markers in a 2-Year Soy Intervention among Premenopausal Women
    Gertraud Maskarinec; Fiscal Year: 2008
    ..The statistical analysis will apply general linear models to compare the levels of inflammatory markers by soy intake, while taking into account the repeated measurement design. [unreadable] [unreadable] [unreadable] [unreadable]..
  25. Breast Cancer, Benign Breast Disease, and Isoflavone Metabolism in Chinese Women
    Johanna Lampe; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable] [unreadable] [unreadable] [unreadable] [unreadable] [unreadable] [unreadable] [unreadable]..
  26. Interaction of PTEN and CDKN1B in Pca susceptibility
    Jianfeng Xu; Fiscal Year: 2008
    ..The results from this study are likely to significant advance our knowledge of prostate cancer risk and begin to explore the underlying biological mechanisms for any observed differences. ..
  27. Image-Guided Pro-Drug/Enzyme Therapy
    Zaver Bhujwalla; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  28. Association of inflammatory genes and prostate cancer
    Jianfeng Xu; Fiscal Year: 2008
    ..Answers to these questions will significantly improve our knowledge of the role of inflammation in prostate cancer and will guide our efforts in identifying additional prostate cancer genes. ..
  29. Aspartame Intake and the Risk of Cancer
    Eva Schernhammer; Fiscal Year: 2008
    ..Our results may help decision-makers formulate guidelines and direct future aspartame studies. Even a null finding would be important in this context. [unreadable] [unreadable] [unreadable]..
  30. VIRAHEP-C Clinical Center
    Anna Lok; Fiscal Year: 2005
    ..abstract_text> ..
  31. NESTED CASE CONTROL STUDY OF MAMMOGRAPHIC DENSITY
    Gertraud Maskarinec; Fiscal Year: 2002
    ....
  32. Genetic Etiologies of Esophageal Barrett's and Cancer
    Charis Eng; Fiscal Year: 2003
    ..This might facilitate molecular diagnostics and early prediction as well as targeted surveillance and prophylaxis. ..
  33. MULTIDICIPLINARY FUNCTIONAL IMAGING OF CANCER
    Zaver Bhujwalla; Fiscal Year: 2002
    ..abstract_text> ..
  34. ENGINEERED THYMIDINE KINASES FOR CANCER GENE THERAPY
    Richard Drake; Fiscal Year: 2002
    ..abstract_text> ..
  35. MOLECULAR REGULATION OF SIGNALING BY IONIZING RADIATION
    Donald Kufe; Fiscal Year: 2002
    ....
  36. Hormone Status Postmenopause: Colonic Bacterial Effects
    Johanna Lampe; Fiscal Year: 2003
    ..The results of this study will provide novel data regarding the relationship of the equol-producer phenotype, a marker of colonic nticrofloral environment, to lifetime estrogen exposure. ..
  37. Bladder Cancer and Urinary Schistosomiasis in Ghana
    Clive Shiff; Fiscal Year: 2004
    ..abstract_text> ..
  38. CATIONIC LIPID/P53 GENE THERAPY IN LUNG CANCER PATIENTS
    Roman Perez Soler; Fiscal Year: 2003
    ..The results of this study will provide initial but very valuable information on the potential use of this new strategy in the treatment of bronchial premalignancy, carcinoma in situ, and endobronchial lung tumors. ..
  39. METABOLISM OF CARCINOGENIC TOBACCO SPECIFIC NITROSAMINES
    Stephen Hecht; Fiscal Year: 2003
    ..abstract_text> ..
  40. USE OF CANCER SCREENING IN A MANAGED CARE ENVIRONMENT
    Kathryn Phillips; Fiscal Year: 2002
    ..The findings will therefore have implications not only for the types of screening examined in this study but also for other health care services. ..
  41. DNA Damage: Fruit & Vegetable Effects in a Feeding Trial
    Johanna Lampe; Fiscal Year: 2005
    ..The existing intervention provides an ideal design in which to evaluate the relationships between biotransformation enzyme systems and DNA damage in humans. ..
  42. Genetic Susceptibility to Infection Related Cancer
    Ikuko Kato; Fiscal Year: 2005
    ..Secondary aims include to examine histopathological correlates of these polymorphisms and to determine whether selected environmental factors modify the above associations. ..
  43. HOST GENES AND COLONIC BACTERIA--PROBING FOR INHERITANCE
    Johanna Lampe; Fiscal Year: 2002
    ..If we can establish that the equol-producer phenotype is an inherited trait, we can then work to identify the associated genotype and determine more effectively whether this is a biomarker of breast cancer risk. ..
  44. Telomere dysfunction, oxidative damage and breast cancer risk
    Jing Shen; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  45. CORI: Consortium Expansion and Database Enhancement
    David Lieberman; Fiscal Year: 2004
    ....
  46. Screening for colortectal cancer in an Asian Community Center
    David Lieberman; Fiscal Year: 2008
    ..This is a new paradigm for screening, which takes advantage of the trust and cultural awareness that exists at the community center and does not rely on the primary care provider. [unreadable] [unreadable] [unreadable] [unreadable]..
  47. Oral Cancer, Chemoprevention, and Anti-Angiogenesis
    Mark Lingen; Fiscal Year: 2009
    ..abstract_text> ..
  48. Molecular Profiling of Premalignant Oral Lesions
    Mark Lingen; Fiscal Year: 2008
    ..This molecular analysis may also greatly improve diagnostic prediction compared to the cellular pattern recognition currently used by pathologists. [unreadable] [unreadable]..
  49. Analysis to enhance sensitivity for membrane proteins
    Samir Hanash; Fiscal Year: 2002
    ....
  50. Depo-Provera and Breast Cancer: Epidemiology/Pathology
    Christopher Li; Fiscal Year: 2009
    ..such as parity and body mass index, modify this association?;and (3) Does the association between DMPA and breast cancer risk vary by histologic type or by the expression of steroid receptors including ERq, ERft, and PR? ..
  51. KALLIKREINS AS DIAGNOSTIC MARKERS OF OVARIAN CARCINOMA
    Eleftherios Diamandis; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  52. Human Kallikrein 4 (hK4): A New Prostatic Biomarker?
    Eleftherios Diamandis; Fiscal Year: 2003
    ..If successful, our research will contribute to the development of new prostatic biomarkers and possibly, to better diagnosis which may lead to better clinical outcomes and reduced healthcare costs. ..
  53. A Serum Marker for Aggressive Prostate Cancer
    Donna M Peehl; Fiscal Year: 2010
    ....
  54. ER Reporter Genes To Predict Response To Endocrine Therapy
    WILLIAM SYMMANS; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  55. c-erbB-2 and Risk of Contralateral Breast Cancer
    Christopher Li; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  56. Automated Tissue Arrayer
    Mark Lingen; Fiscal Year: 2004
    ..An already established Internal Advisory Committee will oversee an equitable and appropriate use by a broad disciplinary group of scientists while giving priority to NIH-supported groups. ..
  57. MOLECULAR DETERMINANTS OF ANGIOGENSIS IN ORAL CANCER
    Mark Lingen; Fiscal Year: 2005
    ....
  58. A New Biomarker for Ovarian Cancer Detection
    Eleftherios Diamandis; Fiscal Year: 2003
    ..In this grant proposal, we describe further studies, which will examine in greater detail, the ability of a test for the amount of this protein in blood to correctly diagnose the presence of ovarian cancer. ..
  59. Molecular Mechanisms in the Treatment of Neuroblastoma
    Valerie Castle; Fiscal Year: 2005
    ..abstract_text> ..
  60. Protein Biomarkers of Cancer Risk in Older Persons
    Christopher Li; Fiscal Year: 2008
    ..unreadable] [unreadable]..
  61. HUPO 2nd Annual World Congress Montreal 2003
    Samir Hanash; Fiscal Year: 2003
    ....
  62. TUMOR CELLS IN CIRCULATION
    Erkki Ruoslahti; Fiscal Year: 2001
    ..Finally, the ability to eliminate tumor cells from the circulation by sFN administration may provide additional protection against tumor cell transfer in bone marrow transplantation used to treat cancer and against tumor metastasis. ..
  63. TISSUE TARGETING WITH PHAGE LIBRARIES
    Erkki Ruoslahti; Fiscal Year: 2001
    ..Major advances in tumor therapies could be realized with this technology. Valuable information on the distinguishing characteristics of different vascular beds, including those undergoing angiogenesis, is also likely to ensue. ..
  64. INTEGRIN REGULATION BY R-RAS
    Erkki Ruoslahti; Fiscal Year: 2002
    ..As the R-ras interactions we have uncovered are novel for the Ras protein superfamily, new information on this important family of cellular regulators and oncoproteins will ensue. ..
  65. Colorectal Cancer Screening: Fecal Blood vs DNA
    David Ahlquist; Fiscal Year: 2004
    ..If the DNA-based test proves to have greater screening accuracy than fecal blood testing, this could translate into more effective cancer control and more efficient use of our limited health care resources. ..
  66. A hypoxia-dependent adenovirus for glioma therapy
    Erwin Van Meir; Fiscal Year: 2005
    ..The translation of these preclinical studies have the potential to directly benefit human health by improving the survival of cancer patients. ..
  67. BIOLOGIC MODIFIER THERAPIES IN AIDS MALIGNANCIES
    Manisha Shah; Fiscal Year: 2004
    ..Collectively, this application provides enhanced strength in intellectual contributions and patient accrual for the AMC, compared to our previous application. ..
  68. CALGB STUDIES OF BREAST CANCER IN THE ELDERLY
    Richard Schilsky; Fiscal Year: 2004
    ..This well integrated project provides a multidisciplinary approach that will address many issues relevant to the treatment of elderly women with breast cancer. ..
  69. Targeting RAF and VEGF Signaling in Thyroid Cancer
    Manisha Shah; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  70. Molecular Changes Associated with PCa bone metastases
    Kenneth Pienta; Fiscal Year: 2006
    ..This knowledge could lead to the development of better biomarkers of disease progression as well as targets for therapy. ..
  71. Regulation of Apoptosis by Integrins
    Erkki Ruoslahti; Fiscal Year: 2007
    ..Cells that become malignant may bypass this pathway in becoming anchorage independent and metastatic. ..
  72. Hypoxia as a target for the treatment of brain tumors
    Erwin Van Meir; Fiscal Year: 2003
    ..The translation of these preclinical studies have the potential to directly benefit human health by improving the survival of children and adults with cancer. ..
  73. Assessing Treatment-Related Harms in Prostate Cancer
    H Welch; Fiscal Year: 2007
    ..The entire process will be repeated on a cohort of men who receive a transurethral resection of the prostate. ..
  74. Molecular Specialization of Tumor Lymphatics
    Erkki Ruoslahti; Fiscal Year: 2008
    ..Promising compounds emerging from these experiments will be tested in pre-clinical cancer models for treatment of cancer and prevention of metastasis. [unreadable] [unreadable]..
  75. FTI Biology & Treatment of Myeloproliferative Disorders
    Jason Gotlib; Fiscal Year: 2005
    ..If clinically efficacious, further studies of R115777 in MPDs will be warranted...
  76. ANGIOGENESIS INHIBITORS: A MECHANISM OF ACTION
    Erkki Ruoslahti; Fiscal Year: 2006
    ..This study may provide important information on the mechanism of action of a class of angiogenesis inhibitors, information that may prove helpful in designing clinical trials for these compounds. [unreadable] [unreadable]..